Pfizer Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PFIZER, and when can generic versions of PFIZER drugs launch?
PFIZER has one hundred and ninety-four approved drugs.
There are forty-eight US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.
There are one thousand and twenty-two patent family members on PFIZER drugs in seventy countries and two hundred and fifty-nine supplementary protection certificates in nineteen countries.
Summary for Pfizer
International Patents: | 1022 |
US Patents: | 48 |
Tradenames: | 159 |
Ingredients: | 130 |
NDAs: | 194 |
Drug Master File Entries: | 3 |
Patent Litigation for Pfizer: | See patent lawsuits for Pfizer |
PTAB Cases with Pfizer as petitioner: | See PTAB cases with Pfizer as petitioner |
Drugs and US Patents for Pfizer
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | MINIPRESS XL | prazosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019775-002 | Jan 29, 1992 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Pfizer | ZITHROMAX | azithromycin | TABLET;ORAL | 050711-001 | Jul 18, 1996 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pfizer | GEOCILLIN | carbenicillin indanyl sodium | TABLET;ORAL | 050435-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Pfizer | PROSTIN VR PEDIATRIC | alprostadil | INJECTABLE;INJECTION | 018484-001 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pfizer | ZYVOX | linezolid | SOLUTION;INTRAVENOUS | 021131-001 | Apr 18, 2000 | AP | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Pfizer
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pfizer | CAVERJECT | alprostadil | INJECTABLE;INJECTION | 020379-004 | May 19, 1997 | 5,741,523 | ⤷ Try a Trial |
Pfizer | ZINECARD | dexrazoxane hydrochloride | INJECTABLE;INJECTION | 020212-001 | May 26, 1995 | 4,275,063 | ⤷ Try a Trial |
Pfizer | TIKOSYN | dofetilide | CAPSULE;ORAL | 020931-002 | Oct 1, 1999 | 6,124,363 | ⤷ Try a Trial |
Pfizer Pharms | ACCUPRIL | quinapril hydrochloride | TABLET;ORAL | 019885-002 | Nov 19, 1991 | 4,344,949*PED | ⤷ Try a Trial |
Pfizer | MINIZIDE | polythiazide; prazosin hydrochloride | CAPSULE;ORAL | 017986-001 | Approved Prior to Jan 1, 1982 | 3,663,706 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PFIZER drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Delayed-release Tablets | 50 mg/0.2 mg | ➤ Subscribe | 2009-06-29 |
➤ Subscribe | Extended-release Tablets | 11 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Capsules | 20 mg, 40 mg, 60 mg and 80 mg | ➤ Subscribe | 2005-02-07 |
➤ Subscribe | Capsules | 75 mg, 100 mg and 125 mg | ➤ Subscribe | 2019-02-04 |
➤ Subscribe | Capsules | 0.125 mg, 0.25 mg, and 0.5 mg | ➤ Subscribe | 2014-05-01 |
➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2005-12-21 |
➤ Subscribe | Injection | 2 mg/mL, 300 mL bag | ➤ Subscribe | 2009-09-01 |
➤ Subscribe | Tablets | 1 g | ➤ Subscribe | 2005-08-23 |
➤ Subscribe | Delayed-release Tablets | 75 mg/0.2 mg | ➤ Subscribe | 2008-11-28 |
➤ Subscribe | Extended-release Tablets | 4 mg and 8 mg | ➤ Subscribe | 2012-10-31 |
➤ Subscribe | Injection | 20 mg/mL, 2 mL and 5 mL vials | ➤ Subscribe | 2004-07-26 |
➤ Subscribe | Capsules | 5 mg and 10 mg | ➤ Subscribe | 2005-06-21 |
➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2011-06-17 |
➤ Subscribe | Oral Suspension | 100 mg/5 mL | ➤ Subscribe | 2009-08-03 |
➤ Subscribe | Injection | 2 mg/mL, 100 mL bag | ➤ Subscribe | 2009-12-29 |
International Patents for Pfizer Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 114466838 | ⤷ Try a Trial |
San Marino | T201600317 | ⤷ Try a Trial |
European Patent Office | 2822953 | ⤷ Try a Trial |
European Patent Office | 3302565 | ⤷ Try a Trial |
Canada | 2690953 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pfizer Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2782584 | LUC00245 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210701 |
0245997 | C300002 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: DOFETILIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/99/121/001 - EU/1/99/121/015 19991129 |
2170860 | 2020027 | Norway | ⤷ Try a Trial | PRODUCT NAME: GLASDEGIB, EVENTUELT I FORM AV ET FARMASOEYTISK AKSEPTABELT SALT, INKLUDERT MALEATSALTET; REG. NO/DATE: EU/1/20/1451 20200703 |
0137145 | SPC/GB97/010 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: GENERIC NAME: IRINOTECANCHEMICAL NAME: (+)-(4S)-4,11-DIETHYL-4-HYDROXY-9-((4-PIPERIDINOPIPERIDINO)CARBONYLOXY)-1H-PYRANO (3',4':6,7) INDOLIZINO(1,2-B) QUINOLINE-3,14-(4H,12H)-DIONE,OPTIONALLY THE HYDROCHLORIDE SALT THEREOF AND OPTIONALLY THE TRIHYDRATE T; REGISTERED: FR 558822.2 19950505; FR 558823.9 19950505; FR 558824.5 19950505; FR 558825.1 19950505; UK 00012/0302 19961017; UK 00012/0303 19961017 |
2958921 | CA 2022 00003 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ABROCITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1593 20211210 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.